Malignant Melanoma
Eshini Perera, Neiraja Gnaneswaran, Ross R. Jennens et al. · Healthcare · 2013
Melanomas are a major cause of premature death from cancer. The gradual decrease in rates of morbidity and mortality has occurred as a result of public health campaigns and improved rates of early diagnosis. Survival of melanoma has increased to over 90%. Management of melanoma involves a number of components: excision, tumor staging, re-excision with negative margins, adjuvant therapies (chemo, radiation or surgery), treatment of stage IV disease, follow-up examination for metastasis, lifestyle modification and counseling. Sentinel lymph node status is an important prognostic factor for survival in patients with a melanoma >1 mm. However, sentinel lymph node biopsies have received partial support due to the limited data regarding the survival advantage of complete lymph node dissection when a micrometastasis is detected in the lymph nodes. Functional mutations in the mitogen-activated pathways are commonly detected in melanomas and these influence the growth control. Therapies that target these pathways are rapidly emerging, and are being shown to increase survival rates in patients. Access to these newer agents can be gained by participation in clinical trials after referral to a multidisciplinary team for staging and re-excision of the scar.
Cited by 51 works. doi:10.3390/healthcare2010001 Open-access PDF
Authors
References
- PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
- Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
- Nivolumab plus Ipilimumab in Advanced Melanoma
- Final Version of 2009 AJCC Melanoma Staging and Classification
- Prognostic Factors Analysis of 17,600 Melanoma Patients: Validation of the American Joint Committee on Cancer Melanoma Staging System
- Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684.
- Survival in BRAF V600–Mutant Advanced Melanoma Treated with Vemurafenib
- Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations